The Relationship Between Resolvin-D1 Level and Vasospasm in Cerebrospinal Fluid in Patients with Aneurysmal Subarachnoid Hemorrhage

Aim: This study explores the role of Resolvin D1 (RvD1) in neuroinflammation and vasospasm following aneurysmal subarachnoid hemorrhage (SAH).The study aims to assess changes in RvD1 levels in cerebrospinal fluid (CSF) after SAH and their relationship with vasospasm, inflammatory markers, and clinical parameters, including Glasgow Coma Scale (GCS) scores. Materials and Methods:Thirty-nine patients diagnosed with spontaneous aneurysmal hemorrhage between May 2021 and May 2023 were included in the study.This study was planned as a prospective study.RvD1 levels were measured in CSF on days 1 and 3 o f bleeding and compared with clinical vasospasm, GCS and CRP values.The rationale for choosing Day 1 and Day 3 for cerebrospinal fluid (CSF) RvD1 measurements is based on the temporal dynamics of early neuroinflammatory response following aneurysmal subarachnoid hemorrhage (SAH).Monitoring these two critical time points provides insight into the early neuroinflammatory trajectory and potential predictive value of RvD1 in relation to vasospasm development.Results: RvD1 levels were significantly higher on the first day in patients with clinical vasospasm.Similarly, elevated RvD1 levels were observed on subsequent days in patients with clinical vasospasm.Serum CRP levels were also significantly higher on the first days of bleeding in the vasospasm group. Conclusion:The findings suggest that RvD1, known for its neuroprotective and anti-inflammatory effects, is elevated in patients with clinical vasospasm, highlighting the role of inflammation in vasospasm pathogenesis after SAH.RvD1 could be used as a potent ial biomarker for predicting clinical vasospasm.